London (RNS) inside information

Date: 01.02.2022 21:02 - GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement

Date: 19.01.2022 7:00 - Tony Wood appointed Chief Scientific Officer
designate, GSK

Date: 23.06.2021 11.00 - New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline

Date: 10.03.2021 01.20 - Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19

Date: 03.02.2021 12:00 - FY 2020 results announcement

Date: 18.05.2020 07:00 - Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Date: 23.12.2019 07:01 - ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

Date: 19.12.2018 07:00 - GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture

Date: 03.12.2018 12:02 - GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company

Date:  30.10.2018 14:30 - ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

Date: 14.06.2018 07:00 - ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients

Date: 27.03.2018 06:00 - GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business

Date: 23.10.2017 07:00 - Shingrix approved in the US for prevention of shingles in adults aged 50 and over

Date: 20.09.2016 07:00 - GSK appoints new CEO     

Date: 19.12.2016 22:01 - ViiV announce phase III results for 2-drug regimen